1. Home
  2. RMCF vs NEUP Comparison

RMCF vs NEUP Comparison

Compare RMCF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$2.40

Market Cap

27.2M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.33

Market Cap

23.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
NEUP
Founded
1981
1996
Country
United States
United States
Employees
N/A
8
Industry
Specialty Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
23.0M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
RMCF
NEUP
Price
$2.40
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
72.7K
25.7K
Earning Date
04-24-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$3.65
52 Week High
$2.99
$21.31

Technical Indicators

Market Signals
Indicator
RMCF
NEUP
Relative Strength Index (RSI) 51.21 57.93
Support Level $1.47 $3.95
Resistance Level $2.60 $4.43
Average True Range (ATR) 0.19 0.13
MACD -0.04 0.04
Stochastic Oscillator 25.48 71.00

Price Performance

Historical Comparison
RMCF
NEUP

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: